Age, Biography and Wiki

René Roy (chemist) was born on 4 November, 1952 in Sherbrooke, Quebec, is a Canadian organic chemist. Discover René Roy (chemist)'s Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 71 years old?

Popular As N/A
Occupation N/A
Age 71 years old
Zodiac Sign Scorpio
Born 4 November 1952
Birthday 4 November
Birthplace Sherbrooke, Quebec
Nationality

We recommend you to check the complete list of Famous People born on 4 November. He is a member of famous with the age 71 years old group.

René Roy (chemist) Height, Weight & Measurements

At 71 years old, René Roy (chemist) height not available right now. We will update René Roy (chemist)'s Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

René Roy (chemist) Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is René Roy (chemist) worth at the age of 71 years old? René Roy (chemist)’s income source is mostly from being a successful . He is from . We have estimated René Roy (chemist)'s net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

René Roy (chemist) Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

1952

René Roy (born November 4, 1952) is a Canadian organic chemist from Quebec, specializing in glycobiology and carbohydrate chemistry.

He is professor emeritus, Department of chemistry, at the Université du Québec à Montréal (UQAM) and associate professor at the Institut National de la Recherche Scientifique (INRS) – Institut Armand-Frappier (IAF).

He is the founder and former director of PharmaQAM, a biopharmaceutical research center based at UQAM, focusing on the discovery of new bioactive molecules, their mechanism of action and the vectorization of drugs.

He is a pioneer in the development of synthetic glycoconjugate vaccines both for human and veterinary health, having co-developed the first and sole marketed semi-synthetic vaccine for human use, preventing bacterial meningitis and pneumonia in developing countries.

1980

René Roy completed his Ph.D. in carbohydrate chemistry from Université de Montréal in 1980, with Stephen Hanessian, developing synthetic methodologies and the syntheses of natural compounds using carbohydrate precursors (Chiron approach).

Immediately after his Ph.D, in 1980, René Roy joined the National Research Council (NRC) in Ottawa where he worked as researcher in the Institute for Biological Sciences.

1985

Then, in 1985, he began his career as professor in the department of chemistry of the University of Ottawa where he served until December 2002.

1993

In parallel, he held the positions of Associate Director of the Ottawa-Carleton Chemistry Institute from 1993 to 1996, Director from 1996 to 1999, and again Associate Director in 2000.

2002

From 2002 to 2004, he was chairman of the American Chemical Society (ACS) Division of Carbohydrate Chemistry and, in 2005, head of the ACS awards committee.

2004

In use since 2004, more than 34 million doses have been distributed to children in several countries including Vietnam, Syria, Brazil, Venezuela and Angola, eradicating the infectious disease in Cuba.

Rene Roy is a cofounder of Glycovax Pharma, a biotech company operating in Montreal, developing glycochemistry-based treatments against cancer and other disease with unmet medical needs.

René Roy uses carbohydrate chemistry to develop neoglycoconjugates and polymers to treat disease related to glycoproteins such as bacterial infections and cancers.

His synthesis of new glycan structures, among which glycopolymers, glycodendrimers, and glycodendrimersomes (terms that he first developed) enabled progress in the area of multivalent molecular recognition mechanisms.

He is known for his work on semi-synthetic glycoconjugate vaccines.

He has designed a breast cancer vaccine prototype.

René Roy has authored more than 370 scientific articles and 2 books on vaccines and glycomimetics.

He has 5 patents to his credit, of which two ended in commercial products

2008

In 2008, he returned to Montreal to teach organic chemistry at the Université du Québec à Montréal.

There, he also founded the PharmaQAM biopharmaceutical research center which gathers some 50 professors and 17 institutions with common interests in the molecular aspects of medicinal chemistry and drug discovery working on new bioactive molecules, their mechanism of action and the way they are vectorized in vivo.

2017

He served as director of PharmaQAM until December 2017.

During his career, René Roy has co-developed meningitis vaccines, for humans and animals, that led to commercial success.

One of them, targeting the Haemophilus influenzae b (HIB) bacteria, has been designed jointly with the Cuban researcher Vincente Verez Bencomo to prevent lethal meningitis and pneumonia in developing countries.

It is the first human semi-synthetic glycoconjugate vaccine approved and remains the only one.